57 patents
Utility
17-hydroxyprogesterone ester-containing oral compositions and related methods
28 Feb 23
The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods.
Chandrashekar Giliyar, Srinivasan Venkateshwaran, Basawaraj Chickmath, Satish Nachaegari, Nachiappan Chidambaram, Mahesh V. Patel
Filed: 13 Jul 20
Utility
Oral testosterone undecanoate therapy
24 Jan 23
The present disclosure provides methods and compositions for testosterone replacement therapy.
Nachiappan Chidambaram, Satish Kumar Nachaegari, Mahesh V. Patel, Kilyoung Kim
Filed: 28 Nov 17
Utility
Compositions and Methods for Treating CNS Disorders
10 Nov 22
The present disclosure is drawn to compositions and methods for treating CNS disorders.
Mahesh V. Patel, Nachiappan Chidambaram, Kilyoung Kim, Kongnara Papangkorn, Benjamin J. Bruno, Kiran Kumar Vangara
Filed: 10 May 22
Utility
Compositions and methods for treating CNS disorders
25 Oct 22
The present disclosure is drawn to compositions and methods for treating CNS disorders.
Mahesh V. Patel, Nachiappan Chidambaram, Kilyoung Kim, Kongnara Papangkorn, Benjamin J. Bruno, Kiran Kumar Vangara
Filed: 10 May 22
Utility
(17-)-3-Oxoandrost-4-EN-17-YL Dodecanoate Compositions and Methods of Preparation and Use
20 Oct 22
Kilyoung Kim, Mahesh V. Patel, Nachiappan Chidambaram, Joel Frank
Filed: 3 Jun 22
Utility
17-hydroxyprogesterone ester-containing oral compositions and related methods
18 Oct 22
The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods.
Chandrashekar Giliyar, Srinivansan Venkateshwaran, Basawaraj Chickmath, Satish Kumar Nachaegari, Nachiappan Chidambaram, Mahesh V. Patel
Filed: 10 Jul 20
Utility
Fixed dose oral testosterone undecanoate compositions and use thereof
11 Oct 22
Disclosed are effective fixed dose oral testosterone undecanoate compositions for use in regimens without dose titration and methods for treatment of patients in need of testosterone replacement therapy.
Mahesh V. Patel, Nachiappan Chidambaram, Kilyoung Kim
Filed: 25 Sep 20
Utility
High-strength testosterone undecanoate compositions
6 Sep 22
The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods.
Chandrashekar Giliyar, Basawaraj Chickmath, Nachiappan Chidambaram, Mahesh V. Patel, Srinivansan Venkateshwaran
Filed: 14 May 19
Utility
High-strength testosterone undecanoate compositions
21 Jun 22
The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods.
Chandrashekar Giliyar, Basawaraj Chickmath, Nachiappan Chidambaram, Mahesh V. Patel, Srinivansan Venkateshwaran
Filed: 8 Apr 20
Utility
High-strength testosterone undecanoate compositions
21 Jun 22
The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods.
Chandrashekar Giliyar, Basawaraj Chickmath, Nachiappan Chidambaram, Mahesh V. Patel, Srinivansan Venkateshwaran
Filed: 30 Jul 20
Utility
Compositions and methods for treating central nervous system disorders
24 May 22
The present disclosure is drawn to compositions and methods for treating CNS disorders.
Mahesh V. Patel, Nachiappan Chidambaram, Kilyoung Kim, Kongnara Papangkorn, Benjamin J. Bruno, Kiran Kumar Vangara
Filed: 7 May 21
Utility
High-strength testosterone undecanoate compositions
26 Apr 22
The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods.
Chandrashekar Giliyar, Basawaraj Chickmath, Nachiappan Chidambaram, Mahesh V. Patel, Srinivansan Venkateshwaran
Filed: 8 Apr 20
Utility
Compositions and Methods of Treating Viral Infections
25 Nov 21
The present disclosure is drawn to a methods of treating viral infections using androgen receptor agonists and compositions and dosages suitable therefor.
Kongnara Papangkorn, Mahesh V. Patel, Nachiappan Chidambaram, Kilyoung Kim, Ben Bruno
Filed: 15 May 20
Utility
Steroidal compositions
6 Jul 21
Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals.
Chandrashekar Giliyar, Nachiappan Chidambaram, Mahesh V. Patel, Srinivasan Venkateshwaran
Filed: 16 Oct 20
Utility
Steroidal Compositions
17 Jun 21
Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals.
Chandrashekar Giliyar, Nachiappan Chidambaram, Mahesh V. Patel, Srinivasan Venkateshwaran
Filed: 24 Feb 21
Utility
Compositions and Their Use In Oral Dosing Regimens
10 Jun 21
Described herein are oral pharmaceutical compositions and their use in testosterone replacement therapy applications.
Mahesh V. Patel, Nachiappan Chidambaram, Satish Nachaegari, Srinivasan Venkateshwaran
Filed: 19 Feb 21
Utility
17-HYDROXYPROGESTERONE Ester-containing Oral Compositions and Related Methods
10 Jun 21
The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods.
Chandrashekar Giliyar, Srinivasan Venkateshwaran, Basawaraj Chickmath, Satish Nachaegari, Nachiappan Chidambaram, Mahesh V. Patel
Filed: 13 Jul 20
Utility
High-strength testosterone undecanoate compositions
13 Apr 21
The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods.
Chandrashekar Giliyar, Basawaraj Chickmath, Nachiappan Chidambaram, Mahesh V. Patel, Srinivansan Venkateshwaran
Filed: 7 Jan 19
Utility
Steroidal Compositions
8 Apr 21
Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals.
Chandrashekar Giliyar, Nachiappan Chidambaram, Mahesh V. Patel, Srinivasan Venkateshwaran
Filed: 8 Dec 20
Utility
Bioavailable Solid State (17- β)-HYDROXY-4-ANDROSTEN-3-ONE Esters
11 Mar 21
Disclosed are bioavailable solid state (17-β)-Hydroxy-4-Androsten-3-one esters suitable for pharmaceutical uses and administration to mammals in need of (17-β)-Hydroxy-4-Androsten-3-one.
Mahesh V. Patel, Nachiappan Chidambaram, Satish Kumar Nachaegari, Srinivasan Venkateshwaran, Joel Frank
Filed: 15 Apr 20